Pfizer licenses Lexicon gene targeting technology
Texas drug discovery company Lexicon Genetics has granted a non-exclusive license to Pfizer for internal research use of its isogenic DNA technology in gene targeting. Pfizer already holds a non-exclusive license from Lexicon for internal research use of Lexicon's patented positive-negative selection technology. Financial details were not disclosed.
Lexicon Genetics is using gene knockout technology to fuel drug discovery programmes in cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and obesity.